PMID- 18782316
OWN - NLM
STAT- MEDLINE
DCOM- 20090206
LR  - 20131121
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 159
IP  - 6
DP  - 2008 Dec
TI  - Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in 
      adults with moderate to severe atopic dermatitis.
PG  - 1322-30
LID - 10.1111/j.1365-2133.2008.08807.x [doi]
AB  - BACKGROUND: Rational health care decision-making based on outcomes and economic 
      evidence is essential to provide the best possible care for individual patients 
      with atopic dermatitis (AD). OBJECTIVES: To describe treatment outcomes and to 
      evaluate resource utilization and associated cost of maintenance use of 
      tacrolimus ointment (MU) vs. standard use of tacrolimus ointment (SU) in adults 
      with AD. METHODS: A pan-European, phase III multicentre randomized clinical trial 
      was conducted. Patients with mild to severe AD were randomized to tacrolimus 0.1% 
      ointment (MU) or vehicle (SU) twice per week for 12 months. Disease exacerbations 
      were treated by using open-label tacrolimus 0.1% ointment twice daily. Resource 
      utilization data were collected prospectively alongside the clinical trial. Costs 
      of pooled resource data were determined using German unit cost data. Direct and 
      indirect costs were considered from third party payer, patient and societal 
      perspectives. RESULTS: All patients with moderate and severe AD were included in 
      a subanalysis, 75 patients in the MU arm (57% moderately affected) and 59 
      patients in the SU arm (59% moderately affected). In patients with moderate AD, 
      the number of disease exacerbations in the MU arm was 2.4 vs. 5.5 in the SU arm 
      (P<0.001); in patients with severe AD corresponding figures were 2.3 vs. 7.4 
      (P<0.001), respectively. Mean+/-SD total annual cost per patient was 
      euro1525+/-1081 (MU) vs. euro1729+/-1209 (SU) in patients with moderate AD and 
      euro2045+/-2013 (MU) vs. euro2904+/-1510 (SU) in patients with severe AD. 
      CONCLUSIONS: Maintenance treatment with 0.1% tacrolimus ointment is more 
      effective and leads to cost savings and improved health-related quality of life 
      in comparison with standard use of 0.1% tacrolimus ointment, especially in 
      patients with severe AD.
FAU - Wollenberg, A
AU  - Wollenberg A
AD  - Klinik und Poliklinik fur Dermatologie und Allergologie, Ludwig-Maximilians 
      Universitat, Munich, Germany.
FAU - Sidhu, M K
AU  - Sidhu MK
FAU - Odeyemi, I
AU  - Odeyemi I
FAU - Dorsch, B
AU  - Dorsch B
FAU - Koehne-Volland, R
AU  - Koehne-Volland R
FAU - Schaff, M
AU  - Schaff M
FAU - Ehlken, B
AU  - Ehlken B
FAU - Berger, K
AU  - Berger K
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080906
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Immunosuppressive Agents)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Adult
MH  - Cost-Benefit Analysis
MH  - Dermatitis, Atopic/*drug therapy/economics
MH  - Drug Administration Schedule
MH  - Female
MH  - Health Care Costs
MH  - Health Status
MH  - Humans
MH  - Immunosuppressive Agents/*economics/therapeutic use
MH  - Male
MH  - Quality of Life
MH  - Tacrolimus/*economics/therapeutic use
MH  - Young Adult
EDAT- 2008/09/11 09:00
MHDA- 2009/02/07 09:00
CRDT- 2008/09/11 09:00
PHST- 2008/09/11 09:00 [pubmed]
PHST- 2009/02/07 09:00 [medline]
PHST- 2008/09/11 09:00 [entrez]
AID - BJD8807 [pii]
AID - 10.1111/j.1365-2133.2008.08807.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2008 Dec;159(6):1322-30. doi: 10.1111/j.1365-2133.2008.08807.x. 
      Epub 2008 Sep 6.